Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 9/20 | 0.40 |
| ▸ | KDM5C | P41229 | 8/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 6/20 | 0.39 |
| ▸ | KDM6B | O15054 | 6/20 | 0.37 |
| ▸ | KDM4A | O75164 | 4/20 | 0.37 |
| ▸ | KDM5A | P29375 | 3/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.37 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 5/20 | 0.37 |
| ▸ | KDM3A | Q9Y4C1 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15636442 | 0.71 | KDM5B (0.52) | KDM4CKDM5CKDM5BKDM6BKDM4A | |
| SCHEMBL16291489 | 0.71 | KDM5C (0.41) | KDM4CKDM5CKDM5BKDM6BKDM4A | |
| SCHEMBL15637002 | 0.69 | KDM4C (0.41) | KDM4CKDM5CKDM5BKDM6BKDM4A | |
| SCHEMBL16291664 | 0.68 | KDM4C (0.43) | KDM4CKDM5CKDM5BKDM6BKDM4A | |
| SCHEMBL16291620 | 0.68 | KDM4C (0.41) | KDM4CKDM5CKDM5BKDM6BKDM4A | |
| SCHEMBL16912745 | 0.68 | FPR2 (0.46) | KDM4CKDM5CKDM5BKDM4AKDM5A | |
| SCHEMBL19549148 | 0.68 | KDM4C (0.41) | KDM4CKDM5CKDM5BKDM6BKDM4A | |
| SCHEMBL16291774 | 0.67 | KDM4C (0.74) | KDM4CKDM5CKDM5BKDM6BKDM4A | |
| SCHEMBL16922676 | 0.67 | KDM4C (0.44) | KDM4CKDM5CKDM5BKDM6BKDM4A | |
| SCHEMBL19676439 | 0.67 | KDM4C (0.39) | KDM4CKDM5CKDM5BKDM6BKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221139-B2 | Inhibitors of histone demethylases | GILEAD SCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170320827-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2017-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320827-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EHMT1, KDM1B, EHMT2 | KDM4C 56/4885KDM5C 31/4885KDM5B 34/4885 |
| US-10221139-B2 | Inhibitors of histone demethylases | EHMT1, KDM1B, EHMT2 | KDM4C 56/4885KDM5C 31/4885KDM5B 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.